Cargando…
A pilot study investigating the role of (18)F‐FDG‐PET in the early identification of chemoradiotherapy response in anal cancer
INTRODUCTION: Anal cancer (AC) is (18)F‐FDG‐PET avid and has been used to evaluate treatment response several months after chemoradiotherapy. This pilot study aimed to assess the utility of semi‐automated contouring methods and quantitative measures of treatment response using (18)F‐FDG‐PET imaging...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714497/ https://www.ncbi.nlm.nih.gov/pubmed/35906833 http://dx.doi.org/10.1002/jmrs.611 |
_version_ | 1784842240815792128 |
---|---|
author | Smith, Drew Joon, Daryl Lim Knight, Kellie Sim, Jenny Schneider, Michal Lau, Eddie Foroudi, Farshad Khoo, Vincent |
author_facet | Smith, Drew Joon, Daryl Lim Knight, Kellie Sim, Jenny Schneider, Michal Lau, Eddie Foroudi, Farshad Khoo, Vincent |
author_sort | Smith, Drew |
collection | PubMed |
description | INTRODUCTION: Anal cancer (AC) is (18)F‐FDG‐PET avid and has been used to evaluate treatment response several months after chemoradiotherapy. This pilot study aimed to assess the utility of semi‐automated contouring methods and quantitative measures of treatment response using (18)F‐FDG‐PET imaging at the early time point of 1‐month post‐chemoradiotherapy. METHODS: Eleven patients with AC referred for chemoradiotherapy were prospectively enrolled into this study, with 10 meeting eligibility requirements. (18)F‐FDG‐PET imaging was obtained pre‐chemoradiotherapy (TP1), and then 1‐month (TP2), 3–6 months (TP3) and 9–12 months (TP4) post‐chemoradiotherapy. Manual and semi‐automated (Threshold) contouring methods were used to define the primary tumour on all (18)F‐FDG‐PET images. Resultant contours from each method were interrogated using quantitative measures, including volume, response index (RI), total lesion glycolysis (TLG), SUV(max), SUV(median) and SUV(mean). Response was assessed quantitatively as reductions in these measures and also qualitatively against established criteria. RESULTS: Nine patients were qualitatively classified as complete metabolic responders at TP2 and all 10 at TP3. All quantitative measures demonstrated significant (P < 0.05) reductions at TP2 for both Manual and Threshold methods. All reduced further at TP3 and again at TP4 for Threshold methods. TLG showed the highest reduction at all post‐chemoradiotherapy time points and classified the most responders for each method at each time point. All patients are recurrence‐free at minimum 4‐year follow‐up. CONCLUSION: Based on our small sample size, semi‐automated methods of disease definition using (18)F‐FDG‐PET imaging are feasible and appear to facilitate quantitative response classification of AC as early as 1‐month post‐chemoradiotherapy. Early identification of treatment response may potentially improve disease management. |
format | Online Article Text |
id | pubmed-9714497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97144972022-12-02 A pilot study investigating the role of (18)F‐FDG‐PET in the early identification of chemoradiotherapy response in anal cancer Smith, Drew Joon, Daryl Lim Knight, Kellie Sim, Jenny Schneider, Michal Lau, Eddie Foroudi, Farshad Khoo, Vincent J Med Radiat Sci Original Articles INTRODUCTION: Anal cancer (AC) is (18)F‐FDG‐PET avid and has been used to evaluate treatment response several months after chemoradiotherapy. This pilot study aimed to assess the utility of semi‐automated contouring methods and quantitative measures of treatment response using (18)F‐FDG‐PET imaging at the early time point of 1‐month post‐chemoradiotherapy. METHODS: Eleven patients with AC referred for chemoradiotherapy were prospectively enrolled into this study, with 10 meeting eligibility requirements. (18)F‐FDG‐PET imaging was obtained pre‐chemoradiotherapy (TP1), and then 1‐month (TP2), 3–6 months (TP3) and 9–12 months (TP4) post‐chemoradiotherapy. Manual and semi‐automated (Threshold) contouring methods were used to define the primary tumour on all (18)F‐FDG‐PET images. Resultant contours from each method were interrogated using quantitative measures, including volume, response index (RI), total lesion glycolysis (TLG), SUV(max), SUV(median) and SUV(mean). Response was assessed quantitatively as reductions in these measures and also qualitatively against established criteria. RESULTS: Nine patients were qualitatively classified as complete metabolic responders at TP2 and all 10 at TP3. All quantitative measures demonstrated significant (P < 0.05) reductions at TP2 for both Manual and Threshold methods. All reduced further at TP3 and again at TP4 for Threshold methods. TLG showed the highest reduction at all post‐chemoradiotherapy time points and classified the most responders for each method at each time point. All patients are recurrence‐free at minimum 4‐year follow‐up. CONCLUSION: Based on our small sample size, semi‐automated methods of disease definition using (18)F‐FDG‐PET imaging are feasible and appear to facilitate quantitative response classification of AC as early as 1‐month post‐chemoradiotherapy. Early identification of treatment response may potentially improve disease management. John Wiley and Sons Inc. 2022-07-30 2022-12 /pmc/articles/PMC9714497/ /pubmed/35906833 http://dx.doi.org/10.1002/jmrs.611 Text en © 2022 The Authors. Journal of Medical Radiation Sciences published by John Wiley & Sons Australia, Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Smith, Drew Joon, Daryl Lim Knight, Kellie Sim, Jenny Schneider, Michal Lau, Eddie Foroudi, Farshad Khoo, Vincent A pilot study investigating the role of (18)F‐FDG‐PET in the early identification of chemoradiotherapy response in anal cancer |
title | A pilot study investigating the role of
(18)F‐FDG‐PET in the early identification of chemoradiotherapy response in anal cancer |
title_full | A pilot study investigating the role of
(18)F‐FDG‐PET in the early identification of chemoradiotherapy response in anal cancer |
title_fullStr | A pilot study investigating the role of
(18)F‐FDG‐PET in the early identification of chemoradiotherapy response in anal cancer |
title_full_unstemmed | A pilot study investigating the role of
(18)F‐FDG‐PET in the early identification of chemoradiotherapy response in anal cancer |
title_short | A pilot study investigating the role of
(18)F‐FDG‐PET in the early identification of chemoradiotherapy response in anal cancer |
title_sort | pilot study investigating the role of
(18)f‐fdg‐pet in the early identification of chemoradiotherapy response in anal cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714497/ https://www.ncbi.nlm.nih.gov/pubmed/35906833 http://dx.doi.org/10.1002/jmrs.611 |
work_keys_str_mv | AT smithdrew apilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT joondaryllim apilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT knightkellie apilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT simjenny apilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT schneidermichal apilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT laueddie apilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT foroudifarshad apilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT khoovincent apilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT smithdrew pilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT joondaryllim pilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT knightkellie pilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT simjenny pilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT schneidermichal pilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT laueddie pilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT foroudifarshad pilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer AT khoovincent pilotstudyinvestigatingtheroleof18ffdgpetintheearlyidentificationofchemoradiotherapyresponseinanalcancer |